Patent application number | Description | Published |
20090118499 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 05-07-2009 |
20090163468 | Fused Bicyclic mTor Inhibitors - Compounds represented by Formula (I) | 06-25-2009 |
20090318511 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS - The present invention provides a compound of formula (I): | 12-24-2009 |
20090325928 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 12-31-2009 |
20100099679 | FUSED BICYCLIC mTOR INHIBITORS - Compounds represented by Formula (I) | 04-22-2010 |
20110190496 | FUSED BICYCLIC mTOR INHIBITORS - Compounds represented by Formula (I) | 08-04-2011 |
20110218183 | Fused Bicyclic mTOR Inhibitors - Compounds represented by Formula (I) | 09-08-2011 |
20120077979 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 03-29-2012 |
20120196847 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 08-02-2012 |
20120225882 | SELECTIVE HYDROXAMATE BASED MMP INHIBITORS - The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition. | 09-06-2012 |
20130165651 | FUSED BICYCLIC mTOR INHIBITORS - Compounds represented by Formula (I) | 06-27-2013 |
20130338159 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS - The present invention includes novel methods of treating a disease or disorder characterized by hyperactivity of Vps34, and compound as Vps34 inhibitors; particularly compounds of Formula I or a pharmaceutically acceptable salt thereof, as well as methods of treating a disease, disorder, or syndrome associated with Vps34 inhibition, particularly hyperproliferative diseases. The present invention also includes pharmaceutical compositions including compounds of formula I and pharmaceutically acceptable salts thereof. | 12-19-2013 |